RT Journal
A1 Tsai TT, Nallamothu BK, Rumsfeld JS
T1 COntraindicated medication use in dialysis patients—reply
JF JAMA
JO JAMA
YR 2010
FD April 21
VO 303
IS 15
SP 1481
OP 1482
DO 10.1001/jama.2010.444
UL http://dx.doi.org/10.1001/jama.2010.444
AB 
In Reply: We agree with Drs Deal and Hollands that the FDA-directed labeling for enoxaparin dosing in dialysis patients undergoing percutaneous coronary intervention is vague. The FDA revised the content and format of prescription drug labeling in 2006 to make prescribing information clearer and more concise.1 Yet, although eptifibatide and enoxaparin are both predominantly renally cleared and both associated with increased bleeding complications in patients undergoing dialysis, the FDA-directed labeling of the 2 drugs is quite different.